|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300
|
|
2.
|
Poeta ML, Manola J, Goldwasser MA, et al:
TP53 mutations and survival in squamous-cell carcinoma of the head
and neck. N Engl J Med. 357:2552–2561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Guimaraes DP and Hainaut P: TP53: a key
gene in human cancer. Biochimie. 84:83–93. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Gasco M and Crook T: The p53 network in
head and neck cancer. Oral Oncol. 39:222–231. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Lowe SW: Cancer therapy and p53. Curr Opin
Oncol. 7:547–553. 1995. View Article : Google Scholar
|
|
7.
|
Velculescu VE and El-Deiry WS: Biological
and clinical importance of the p53 tumor suppressor gene. Clin
Chem. 42:858–868. 1996.PubMed/NCBI
|
|
8.
|
Ota I, Ohnishi K, Takahashi A, et al:
Transfection with mutant p53 gene inhibits heat-induced apoptosis
in a head and neck cell line of human squamous cell carcinoma. Int
J Radiat Oncol Biol Phys. 47:495–501. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Takahashi A: Different inducibility of
radiation- or heat-induced p53-dependent apoptosis after acute or
chronic irradiation in human cultured squamous cell carcinoma
cells. Int J Radiat Biol. 77:215–224. 2001. View Article : Google Scholar
|
|
10.
|
Ohnishi K, Ota I, Takahashi A, Yane K,
Matsumoto H and Ohnishi T: Transfection of mutant p53 gene
depresses X-ray- or CDDP-induced apoptosis in a human squamous cell
carcinoma of the head and neck. Apoptosis. 7:367–372. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Asakawa I, Yoshimura H, Takahashi A, et
al: Radiation-induced growth inhibition in transplanted human
tongue carcinomas with different p53 gene status. Anticancer Res.
22:2037–2043. 2002.PubMed/NCBI
|
|
12.
|
Tamamoto T, Yoshimura H, Takahashi A, et
al: Heat-induced growth inhibition and apoptosis in transplanted
human head and neck squamous cell carcinomas with different status
of p53. Int J Hyperthermia. 19:590–597. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yuki K, Takahashi A, Ota I, et al:
Sensitization by glycerol for CDDP-therapy against human cultured
cancer cells and tumors bearing mutated p53 gene. Apoptosis.
9:853–859. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lane DP and Crawford LV: T antigen is
bound to a host protein in SV40-transformed cells. Nature.
278:261–263. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Nigro JM, Baker SJ, Preisinger AC, et al:
Mutations in the p53 gene occur in diverse human tumour types.
Nature. 342:705–708. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Finlay CA, Hinds PW and Levine AJ: The p53
proto-oncogene can act as a suppressor of transformation. Cell.
57:1083–1093. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Efeyan A and Serrano M: p53: guardian of
the genome and policeman of the oncogenes. Cell Cycle. 6:1006–1010.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Slee EA, O'Connor DJ and Lu X: To die or
not to die: how does p53 decide? Oncogene. 23:2809–2818. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Vousden KH and Lu X: Live or let die: the
cell's response to p53. Nat Rev Cancer. 2:594–604. 2002.
|
|
21.
|
Bambara RA and Jessee CB: Properties of
DNA polymerases delta and epsilon, and their roles in eukaryotic
DNA replication. Biochim Biophys Acta. 1088:11–24. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
El-Deiry WS, Tokino T, Velculescu VE, et
al: WAF1, a potential mediator of p53 tumor suppression. Cell.
75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Deng C, Zhang P, Harper JW, Elledge SJ and
Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but
are defective in G1 checkpoint control. Cell. 82:675–684. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kastan MB, Zhan Q, el-Deiry WS, et al: A
mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is
defective in ataxia-telangiectasia. Cell. 71:587–597. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Smith ML, Kontny HU, Zhan Q, Sreenath A,
O'Connor PM and Fornace AJ Jr: Antisense GADD45 expression results
in decreased DNA repair and sensitizes cells to u.v.-irradiation or
cisplatin. Oncogene. 13:2255–2263. 1996.PubMed/NCBI
|
|
26.
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Yu J and Zhang L: No PUMA, no death:
implications for p53-dependent apoptosis. Cancer Cell. 4:248–249.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Owen-Schaub LB, Zhang W, Cusack JC, et al:
Wild-type human p53 and a temperature-sensitive mutant induce
Fas/APO-1 expression. Mol Cell Biol. 15:3032–3040. 1995.PubMed/NCBI
|
|
29.
|
Israeli D, Tessler E, Haupt Y, et al: A
novel p53-inducible gene, PAG608, encodes a nuclear zinc finger
protein whose overexpression promotes apoptosis. EMBO J.
16:4384–4392. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Haupt S, Louria-Hayon I and Haupt Y: P53
licensed to kill? Operating the assassin. J Cell Biochem. 88:76–82.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Barak Y and Oren M: Enhanced binding of a
95 kDa protein to p53 in cells undergoing p53-mediated growth
arrest. EMBO J. 11:2115–2121. 1992.PubMed/NCBI
|
|
32.
|
Brooks CL and Gu W: Ubiquitination,
phosphorylation and acetylation: the molecular basis for p53
regulation. Curr Opin Cell Biol. 15:164–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Valenzuela MT, Guerrero R, Nunez MI, et
al: PARP-1 modifies the effectiveness of p53-mediated DNA damage
response. Oncogene. 21:1108–1116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Schmidt D and Muller S: Members of the
PIAS family act as SUMO ligases for c-Jun and p53 and repress p53
activity. Proc Natl Acad Sci USA. 99:2872–2877. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Melchior F and Hengst L: SUMO-1 and p53.
Cell Cycle. 1:245–249. 2002. View Article : Google Scholar
|
|
36.
|
Siliciano JD, Canman CE, Taya Y, Sakaguchi
K, Appella E and Kastan MB: DNA damage induces phosphorylation of
the amino terminus of p53. Genes Dev. 11:3471–3481. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Shieh SY, Ahn J, Tamai K, Taya Y and
Prives C: The human homologs of checkpoint kinases Chk1 and Cds1
(Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.
Genes Dev. 14:289–300. 2000.PubMed/NCBI
|
|
38.
|
Urban G, Golden T, Aragon IV, et al:
Identification of a functional link for the p53 tumor suppressor
protein in dexamethasone-induced growth suppression. J Biol Chem.
278:9747–9753. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Oda K, Arakawa H, Tanaka T, et al:
p53AIP1, a potential mediator of p53-dependent apoptosis, and its
regulation by Ser-46-phosphorylated p53. Cell. 102:849–862. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Saito S, Goodarzi AA, Higashimoto Y, et
al: ATM mediates phosphorylation at multiple p53 sites, including
Ser(46), in response to ionizing radiation. J Biol Chem.
277:12491–12494. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Ohnishi T, Matsumoto H, Takahashi A,
Shimura M and Majima HJ: Accumulation of mutant p53 and hsp72 by
heat treatment, and their association in a human glioblastoma cell
line. Int J Hyperthermia. 11:663–671. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Matsumoto H, Wang X and Ohnishi T: Binding
between wild-type p53 and hsp72 accumulated after UV and gamma-ray
irradiation. Cancer Lett. 92:127–133. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Petros AM, Gunasekera A, Xu N, Olejniczak
ET and Fesik SW: Defining the p53 DNA-binding
domain/Bcl-x(L)-binding interface using NMR. FEBS Lett.
559:171–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Takahashi A, Ota I, Tamamoto T, et al:
p53-dependent hyper-thermic enhancement of tumour growth inhibition
by X-ray or carbon-ion beam irradiation. Int J Hyperthermia.
19:145–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Fujiwara T, Cai DW, Georges RN,
Mukhopadhyay T, Grimm EA and Roth JA: Therapeutic effect of a
retroviral wild-type p53 expression vector in an orthotopic lung
cancer model. J Natl Cancer Inst. 86:1458–1462. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Scardigli R, Bossi G, Blandino G,
Crescenzi M, Soddu S and Sacchi A: Expression of exogenous wt-p53
does not affect normal hematopoiesis: implications for bone marrow
purging. Gene Ther. 4:1371–1378. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Bossi G, Mazzaro G, Porrello A, Crescenzi
M, Soddu S and Sacchi A: Wild-type p53 gene transfer is not
detrimental to normal cells in vivo: implications for tumor gene
therapy. Oncogene. 23:418–425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Vecil GG and Lang FF: Clinical trials of
adenoviruses in brain tumors: a review of Ad-p53 and oncolytic
adenoviruses. J Neurooncol. 65:237–246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Pearson S, Jia H and Kandachi K: China
approves first gene therapy. Nat Biotechnol. 22:3–4. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI
|
|
51.
|
Bischoff JR, Kirn DH, Williams A, et al:
An adenovirus mutant that replicates selectively in p53-deficient
human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Bossi G and Sacchi A: Restoration of
wild-type p53 function in human cancer: relevance for tumor
therapy. Head Neck. 29:272–284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Ohnishi K, Ota I, Takahashi A and Ohnishi
T: Glycerol restores p53-dependent radiosensitivity of human head
and neck cancer cells bearing mutant p53. Br J Cancer.
83:1735–1739. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Welch WJ and Brown CR: Influence of
molecular and chemical chaperones on protein folding. Cell Stress
Chaperones. 1:109–115. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Thomas PJ, Qu BH and Pedersen PL:
Defective protein folding as a basis of human disease. Trends
Biochem Sci. 20:456–459. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Ohnishi K, Ota I, Yane K, et al: Glycerol
as a chemical chaperone enhances radiation-induced apoptosis in
anaplastic thyroid carcinoma cells. Mol Cancer. 1:42002. View Article : Google Scholar
|
|
57.
|
Imai Y, Ohnishi K, Yasumoto J, et al:
Glycerol enhances radio-sensitivity in a human oral squamous cell
carcinoma cell line (Ca9-22) bearing a mutant p53 gene via
Bax-mediated induction of apoptosis. Oral Oncol. 41:631–636. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Ohnishi T, Ohnishi K and Takahashi A:
Glycerol restores heat-induced p53-dependent apoptosis of human
glioblastoma cells bearing mutant p53. BMC Biotechnol. 2:62002.
View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Yuki K, Takahashi A, Ota I, et al:
Glycerol enhances CDDP-induced growth inhibition of thyroid
anaplastic carcinoma tumor carrying mutated p53 gene. Oncol Rep.
11:821–824. 2004.PubMed/NCBI
|
|
60.
|
Bargonetti J, Friedman PN, Kern SE,
Vogelstein B and Prives C: Wild-type but not mutant p53
immunopurified proteins bind to sequences adjacent to the SV40
origin of replication. Cell. 65:1083–1091. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Cho Y, Gorina S, Jeffrey PD and Pavletich
NP: Crystal structure of a p53 tumor suppressor-DNA complex:
understanding tumorigenic mutations. Science. 265:346–355. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Halazonetis TD and Kandil AN:
Conformational shifts propagate from the oligomerization domain of
p53 to its tetrameric DNA binding domain and restore DNA binding to
select p53 mutants. EMBO J. 12:5057–5064. 1993.PubMed/NCBI
|
|
63.
|
Hupp TR, Meek DW, Midgley CA and Lane DP:
Regulation of the specific DNA binding function of p53. Cell.
71:875–886. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Hupp TR and Lane DP: Allosteric activation
of latent p53 tetramers. Curr Biol. 4:865–875. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Hupp TR, Sparks A and Lane DP: Small
peptides activate the latent sequence-specific DNA binding function
of p53. Cell. 83:237–245. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Hupp TR, Meek DW, Midgley CA and Lane DP:
Activation of the cryptic DNA binding function of mutant forms of
p53. Nucleic Acids Res. 21:3167–3174. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Abarzua P, LoSardo JE, Gubler ML, et al:
Restoration of the transcription activation function to mutant p53
in human cancer cells. Oncogene. 13:2477–2482. 1996.PubMed/NCBI
|
|
68.
|
Selivanova G, Iotsova V, Okan I, et al:
Restoration of the growth suppression function of mutant p53 by a
synthetic peptide derived from the p53 C-terminal domain. Nat Med.
3:632–638. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Kim AL, Raffo AJ, Brandt-Rauf PW, et al:
Conformational and molecular basis for induction of apoptosis by a
p53 C-terminal peptide in human cancer cells. J Biol Chem.
274:34924–34931. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Ohnishi K, Inaba H, Yasumoto J, Yuki K,
Takahashi A and Ohnishi T: C-terminal peptides of p53 molecules
enhance radiation-induced apoptosis in human mutant p53 cancer
cells. Apoptosis. 9:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Selivanova G, Ryabchenko L, Jansson E,
Iotsova V and Wiman KG: Reactivation of mutant p53 through
interaction of a C-terminal peptide with the core domain. Mol Cell
Biol. 19:3395–3402. 1999.PubMed/NCBI
|
|
72.
|
Foster BA, Coffey HA, Morin MJ and
Rastinejad F: Pharmacological rescue of mutant p53 conformation and
function. Science. 286:2507–2510. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Takimoto R, Wang W, Dicker DT, Rastinejad
F, Lyssikatos J and el-Deiry WS: The mutant p53-conformation
modifying drug, CP-31398, can induce apoptosis of human cancer
cells and can stabilize wild-type p53 protein. Cancer Biol Ther.
1:47–55. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Rippin TM, Bykov VJ, Freund SM, Selivanova
G, Wiman KG and Fersht AR: Characterization of the p53-rescue drug
CP-31398 in vitro and in living cells. Oncogene. 21:2119–2129.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Bykov VJ, Issaeva N, Shilov A, et al:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Peng Y, Li C, Chen L, Sebti S and Chen J:
Rescue of mutant p53 transcription function by ellipticine.
Oncogene. 22:4478–4487. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Vassilev LT, Vu BT, Graves B, et al: In
vivo activation of the p53 pathway by small-molecule antagonists of
MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Blakely EA and Kronenberg A: Heavy-ion
radiobiology: new approaches to delineate mechanisms underlying
enhanced biological effectiveness. Radiat Res. 150:S126–S145. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Guida P, Vazquez ME and Otto S: Cytotoxic
effects of low- and high-LET radiation on human neuronal progenitor
cells: induction of apoptosis and TP53 gene expression. Radiat Res.
164:545–551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Demizu Y, Kagawa K, Ejima Y, et al: Cell
biological basis for combination radiotherapy using heavy-ion beams
and high-energy X-rays. Radiother Oncol. 71:207–211. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Debus J, Jackel O, Kraft G and
Wannenmacher M: Is there a role for heavy ion beam therapy? Recent
Results Cancer Res. 150:170–182. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
Takahashi A, Matsumoto H, Yuki K, et al:
High-LET radiation enhanced apoptosis but not necrosis regardless
of p53 status. Int J Radiat Oncol Biol Phys. 60:591–597. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
83.
|
Takahashi A, Matsumoto H, Furusawa Y,
Ohnishi K, Ishioka N and Ohnishi T: Apoptosis induced by high-LET
radiations is not affected by cellular p53 gene status. Int J
Radiat Biol. 81:581–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
84.
|
Takahashi A, Ohnishi K, Wang X, et al: The
dependence of p53 on the radiation enhancement of thermosensitivity
at different LET. Int J Radiat Oncol Biol Phys. 47:489–494. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
85.
|
Yamakawa N, Takahashi A, Mori E, et al:
High LET radiation enhances apoptosis in mutated p53 cancer cells
through caspase-9 activation. Cancer Sci. 99:1455–1460. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
86.
|
Peng Y, Zhang Q, Nagasawa H, Okayasu R,
Liber HL and Bedford JS: Silencing expression of the catalytic
subunit of DNA-dependent protein kinase by small interfering RNA
sensitizes human cells for radiation-induced chromosome damage,
cell killing, and mutation. Cancer Res. 62:6400–6404. 2002.
|
|
87.
|
Collis SJ, Swartz MJ, Nelson WG and
DeWeese TL: Enhanced radiation and chemotherapy-mediated cell
killing of human cancer cells by small inhibitory RNA silencing of
DNA repair factors. Cancer Res. 63:1550–1554. 2003.PubMed/NCBI
|
|
88.
|
Tauchi H, Kobayashi J, Morishima K, et al:
Nbs1 is essential for DNA repair by homologous recombination in
higher vertebrate cells. Nature. 420:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
89.
|
Sakamoto S, Iijima K, Mochizuki D, et al:
Homologous recombination repair is regulated by domains at the N-
and C-terminus of NBS1 and is dissociated with ATM functions.
Oncogene. 26:6002–6009. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90.
|
Tauchi H, Matsuura S, Kobayashi J,
Sakamoto S and Komatsu K: Nijmegen breakage syndrome gene, NBS1,
and molecular links to factors for genome stability. Oncogene.
21:8967–8980. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
91.
|
Nelms BE, Maser RS, MacKay JF, Lagally MG
and Petrini JH: In situ visualization of DNA double-strand break
repair in human fibroblasts. Science. 280:590–592. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
92.
|
Zhang Y, Lim CU, Williams ES, et al: NBS1
knockdown by small interfering RNA increases ionizing radiation
mutagenesis and telomere association in human cells. Cancer Res.
65:5544–5553. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
93.
|
Lee SJ, Dimtchev A, Lavin MF, Dritschilo A
and Jung M: A novel ionizing radiation-induced signaling pathway
that activates the transcription factor NF-kappaB. Oncogene.
17:1821–1826. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
94.
|
Orlowski RZ and Baldwin AS Jr: NF-kappaB
as a therapeutic target in cancer. Trends Mol Med. 8:385–389. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
95.
|
Yamagishi N, Miyakoshi J and Takebe H:
Enhanced radiosensitivity by inhibition of nuclear factor kappa B
activation in human malignant glioma cells. Int J Radiat Biol.
72:157–162. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
96.
|
Habraken Y, Jolois O and Piette J:
Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1
and MLH1 in NF-kappaB activation by camptothecin and X-ray.
Oncogene. 22:6090–6099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
97.
|
LaCasse EC, Baird S, Korneluk RG and
MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging
role in cancer. Oncogene. 17:3247–3259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
98.
|
Ohnishi K, Scuric Z, Schiestl RH, Okamoto
N, Takahashi A and Ohnishi T: siRNA targeting NBS1 or XIAP
increases radiation sensitivity of human cancer cells independent
of TP53 status. Radiat Res. 166:454–462. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99.
|
Ohnishi K, Scuric Z, Yau D, et al:
Heat-induced phosphorylation of NBS1 in human skin fibroblast
cells. J Cell Biochem. 99:1642–1650. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
100.
|
Okamoto N, Takahashi A, Ota I, et al:
siRNA targeted for NBS1 enhances heat sensitivity in human
anaplastic thyroid carcinoma cells. Int J Hyperthermia.
27:297–304
|
|
101.
|
Ohnishi K, Nagata Y, Takahashi A,
Taniguchi S and Ohnishi T: Effective enhancement of X-ray-induced
apoptosis in human cancer cells with mutated p53 by siRNA targeting
XIAP. Oncol Rep. 20:57–61. 2008.PubMed/NCBI
|
|
102.
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
103.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
104.
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
105.
|
Wang F, Arun P, Friedman J, Chen Z and Van
Waes C: Current and potential inflammation targeted therapies in
head and neck cancer. Curr Opin Pharmacol. 9:389–395. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
106.
|
Raimondi AR, Molinolo A and Gutkind JS:
Rapamycin prevents early onset of tumorigenesis in an oral-specific
K-ras and p53 two-hit carcinogenesis model. Cancer Res.
69:4159–4166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
107.
|
Shaw M, Cohen P and Alessi DR: The
activation of protein kinase B by H2O2 or
heat shock is mediated by phosphoinositide 3-kinase and not by
mitogen-activated protein kinase-activated protein kinase-2.
Biochem J. 336:241–246. 1998.
|
|
108.
|
Rosenzweig KE, Youmell MB, Palayoor ST and
Price BD: Radiosensitization of human tumor cells by the
phosphatidylinositol3-kinase inhibitors wortmannin and LY294002
correlates with inhibition of DNA-dependent protein kinase and
prolonged G2-M delay. Clin Cancer Res. 3:1149–1156. 1997.
|
|
109.
|
Gupta AK, Cerniglia GJ, Mick R, et al:
Radiation sensitization of human cancer cells in vivo by inhibiting
the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys.
56:846–853. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
110.
|
Ohnishi K, Yasumoto J, Takahashi A and
Ohnishi T: LY294002, an inhibitor of PI-3K, enhances heat
sensitivity independently of p53 status in human lung cancer cells.
Int J Oncol. 29:249–253. 2006.PubMed/NCBI
|
|
111.
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
|
112.
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
|
|
113.
|
Beuvink I, Boulay A, Fumagalli S, et al:
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged
induced apoptosis through inhibition of p21 translation. Cell.
120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
114.
|
Majumder PK, Febbo PG, Bikoff R, et al:
mTOR inhibition reverses Akt-dependent prostate intraepithelial
neoplasia through regulation of apoptotic and HIF-1-dependent
pathways. Nat Med. 10:594–601. 2004. View
Article : Google Scholar
|
|
115.
|
Boulay A, Zumstein-Mecker S, Stephan C, et
al: Antitumor efficacy of intermittent treatment schedules with the
rapamycin derivative RAD001 correlates with prolonged inactivation
of ribosomal protein S6 kinase 1 in peripheral blood mononuclear
cells. Cancer Res. 64:252–261. 2004. View Article : Google Scholar
|
|
116.
|
Mabuchi S, Altomare DA, Cheung M, et al:
RAD001 inhibits human ovarian cancer cell proliferation, enhances
cisplatin-induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar
|
|
117.
|
Cao C, Subhawong T, Albert JM, et al:
Inhibition of mammalian target of rapamycin or apoptotic pathway
induces autophagy and radiosensitizes PTEN null prostate cancer
cells. Cancer Res. 66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
118.
|
Albert JM, Kim KW, Cao C and Lu B:
Targeting the Akt/mammalian target of rapamycin pathway for
radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
119.
|
Nagata Y, Takahashi A, Ohnishi K, et al:
Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of
lung cancer cells having different p53 gene status. Int J Oncol.
37:1001–1010
|
